Novel Supreme TM DES with Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation after DES implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial

Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy

(2020) Ovidio De Filippo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adverse events beyond 1 year after percutaneous coronary intervention

(2020) Mahesh V. Madhavan et al.   CURRENT OPINION IN CARDIOLOGY

Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial

(2019) Azfar Zaman et al.   LANCET

A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial

(2018) Robbert J de Winter et al.   LANCET

Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial

(2017) David E Kandzari et al.   LANCET

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

(2016) Glenn N. Levine et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Long-Term Safety of Drug-Eluting and Bare-Metal Stents

(2015) Tullio Palmerini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Vascular restoration: Is there a window of opportunity?

(2015) Jianhua Sun et al.   MEDICAL HYPOTHESES

2014 ESC/EACTS Guidelines on myocardial revascularization

(2014)   EUROPEAN HEART JOURNAL

Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial

(2014) Thomas Pilgrim et al.   LANCET

Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials

(2012) G. G. Stefanini et al.   EUROPEAN HEART JOURNAL

Third Universal Definition of Myocardial Infarction

(2012) Kristian Thygesen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A Prospective, Randomized Evaluation of a Novel Everolimus-Eluting Coronary Stent

(2011) Gregg W. Stone et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period

(2009) S. Schulz et al.   EUROPEAN HEART JOURNAL